RareResearch.AI
← Back to atlas

E864K

Category 3/4 — Most DruggablePathogenic/Likely pathogenicLumenal · predictedσ-1 candidateEditorial
GlutamateLysine at position 864 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Charge-flip mutation at the very C-terminal edge of the lumenal domain — glutamate's negative carboxylate replaced by lysine's positive amine, in a region where pLDDT (59) signals borderline confidence and the structural interpretation requires explicit caution.

Interactive 3D Structure

Wild-type reference
Wild-type E864 — ionic bond to R697
Fullscreen ↗
DynaMut2 mutant · E864K
Mutant K864 — ionic bond to R697 lost (6 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

6 lost1 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Ionic bondR697Lost
Ionic bondK862Lost
Hydrogen bondR697Lost
Hydrogen bondK862K862Preserved
Hydrogen bondD866D866Preserved
Polar contactR697Lost
Polar contactK862Lost
Polar contactD866D866Preserved
Van der WaalsD866Gained
HydrophobicK843Lost
HydrophobicK862K862Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.26kcal/mol
Destabilising — mild
AlphaMissense
0.842
LPath
AlphaFold pLDDT
59
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Reduced confidence · Lumenal
  • pLDDT 59.28 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Wolfram-like syndrome; Retinal dystrophy; Rare genetic deafness; Nonsyndromic genetic hearing loss
InheritanceAutosomal dominant (deafness 6) and Wolfram-like spectrum forms documented.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2590G>A
ClinVar accessionVCV000004526
Last evaluated2024/11/08 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic/Likely pathogenic for Hearing loss, inheritance unstated (inheritance not specified); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Retinal dystrophy (inheritance not specified); Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are dominant WFS1-related disorders and are clinically distinct from classic recessive Wolfram syndrome. This classification is not a statement about Wolfram syndrome severity.

  • Hearing loss, inheritance unstatedinheritance not specifiedsubmitted as: Rare genetic deafness; Nonsyndromic genetic hearing loss
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss; Autosomal dominant nonsyndromic hearing loss 6
  • Retinal dystrophyinheritance not specifiedsubmitted as: Retinal dystrophy
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
Absent from gnomAD v4
Homozygotes
Not available

No population breakdown — the variant is absent from gnomAD v4, so no ancestry group has an observed frequency.

No homozygotes — the variant is absent from gnomAD v4 altogether.

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

E864 has only four neighbors within 5 Angstrom: His865 (2.41 Angstrom), Ile863 (2.43 Angstrom), Asp866 (4.75 Angstrom), and Lys862 (4.80 Angstrom). The minimal contact set is itself diagnostic — at pLDDT 59, AlphaFold is signaling that the local conformation is partially ordered or solvent-exposed rather than packed against a stable core. The neighborhood is locally informative nonetheless: a histidine, a downstream aspartate, and an upstream lysine all sit within the polar shell.

In the wild-type configuration, E864's carboxylate plausibly forms a salt bridge with K862 (4.80 Angstrom is within typical salt-bridge range when sidechain conformations are accounted for), and may hydrogen-bond to His865 depending on the imidazole's protonation state. The downstream Asp866 contributes additional negative charge to the local cluster — two glutamates/aspartates and one lysine, balanced.

E864K flips the charge sign on E864. The K862-E864 salt bridge is destroyed because both residues are now positively charged — they will electrostatically repel rather than attract. The local cluster goes from -E864 ... +K862 ... -D866 (a balanced charge triad) to +K864 ... +K862 ... -D866 (a positive pair next to a negative residue). The geometric consequence is that K862 and K864 likely splay apart, dragging the backbone with them, while D866's carboxylate may rotate to form a new salt bridge with one of the lysines.

DynaMut2's DeltaDeltaG of -0.26 kcal/mol substantially under-reads the disruption — energy functions tend to compensate the electrostatic loss when a new contact forms, even if that contact is geometrically forced. AlphaMissense at 0.842 reads the true severity. The clinical phenotype is broad: retinal dystrophy, autosomal dominant nonsyndromic hearing loss 6, Wolfram-like syndrome — consistent with a C-terminal lumenal disruption affecting the function of the lumenal sensor face.

Amino-acid chemistry
Glutamate (negatively charged carboxylate side chain, ~5 Angstrom long) to Lysine (positively charged primary amine on a long aliphatic side chain, ~6.5 Angstrom long) at position 864. The substitution flips the charge sign in a single mutation — a classical electrostatic-disruption signature.
Position in the protein
Position 864 sits near the C-terminal end of the lumenal domain (residues 653-869), just 5 residues before the lumenal-domain boundary. pLDDT 59.28 is borderline: above the IDR threshold (50) but below high-confidence (70+). The residue is modelable but the precise geometry should be treated with appropriate uncertainty.

Druggability Assessment

Final classification: Category 4 — Stable Fold, Function Disrupted. The DeltaDeltaG magnitude (0.26 kcal/mol) is small, the pLDDT (59) is borderline, and the charge-flip biology is the dominant mechanism. The Atlas should treat E864K as a functional-site disruption variant rather than a misfolding variant: the gross fold survives, but a specific electrostatic signature near the C-terminal edge of the lumenal domain is inverted. For druggability, the borderline pLDDT introduces caveats. Docking against a region with pLDDT 59 requires either local refinement or experimental structure determination — the AlphaFold model is acceptable for hypothesis generation but should not be the sole basis for compound design. The therapeutic frame is still pharmacological chaperone or charge-mimicking small molecule, but the model uncertainty argues for parallel wet-lab validation of the K862-E864-D866 cluster's structural arrangement.

Why this matters

E864K is a useful Atlas example of how the schema must handle borderline pLDDT honestly. A naive interpretation would push this variant into the Cat 5 IDR-exclusion bucket; the structural signal (a clear charge-flip near an annotated salt-bridge candidate) and the AlphaMissense score (0.842) argue against exclusion. The right answer is Category 4 with an explicit modeling caveat — not a default discard. Clinically, the autosomal dominant deafness 6 phenotype at this variant is notable. AD-DFNA6 carries a distinct disease trajectory from classical autosomal recessive Wolfram syndrome, and E864K is one of the lumenal-domain variants where the dominant inheritance pattern is best documented. This makes E864K a clinical reference variant for the dominantly-inherited Wolfram-spectrum hearing loss form.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E864K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E864K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal
Natural variant864864 · in WFSL; dbSNP:rs74315205